Pegcetacoplan (DB16694): A Comprehensive Monograph on a First-in-Class C3 Complement Inhibitor

I. Executive Summary

Pegcetacoplan represents a significant advancement in the field of complement-targeted therapeutics, establishing a new class of drugs by inhibiting the central component of the complement cascade, protein C3.[1] This report provides a comprehensive analysis of its pharmacology, clinical development, safety profile, and regulatory journey. As a first-in-class, pegylated synthetic peptide, Pegcetacoplan’s mechanism of proximal complement inhibition offers a broader and more comprehensive regulation of the immune system's complement pathways compared to previous terminal complement inhibitors. This unique mechanism has enabled its successful application across a diverse range of debilitating diseases.

The drug has secured regulatory approval for three distinct indications, each addressing a significant unmet medical need. For adults with Paroxysmal Nocturnal Hemoglobinuria (PNH), Pegcetacoplan (marketed as Empaveli®) has demonstrated superiority over the previous standard of care, eculizumab, by effectively controlling both intravascular and extravascular hemolysis, leading to marked improvements in hemoglobin levels and a reduction in transfusion dependence for patients who remained anemic on C5 inhibitors.[4] For Geographic Atrophy (GA) secondary to age-related macular degeneration, the intravitreal formulation (Syfovre®) became the first-ever therapy approved by the U.S. Food and Drug Administration (FDA), slowing the anatomical progression of a leading cause of blindness. However, this indication has faced regulatory divergence, with the European Medicines Agency (EMA) concluding that the anatomical benefit did not translate into a sufficiently meaningful functional outcome to outweigh the risks.[7] Most recently, Pegcetacoplan was approved for C3 Glomerulopathy (C3G) and Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN), where it is the first treatment to show significant reductions in proteinuria, stabilization of kidney function, and clearance of pathogenic C3 deposits.[9]

This broad utility is counterbalanced by a significant safety consideration inherent to its mechanism: an increased risk of serious and life-threatening infections caused by encapsulated bacteria. This risk necessitates a mandatory vaccination protocol and a restricted Risk Evaluation and Mitigation Strategy (REMS) program to ensure patient safety.[2] This monograph synthesizes the extensive body of evidence for Pegcetacoplan, detailing the scientific rationale, pivotal clinical trial outcomes, and the nuanced risk-benefit profile that defines its place in modern medicine.

II. Introduction to Pegcetacoplan

Pegcetacoplan is a novel biopharmaceutical agent designed to modulate the complement system, a critical component of innate immunity. Its development marks a strategic shift in therapeutic approaches to complement-mediated diseases, moving from downstream, terminal pathway inhibition to a more central, upstream point of control.

2.1. Chemical and Structural Characteristics

Pegcetacoplan is a symmetrical molecule engineered for high affinity, specificity, and an extended pharmacokinetic profile.[12] Its structure consists of two identical synthetic, cyclic pentadecapeptides that are covalently bound to the opposing ends of a linear 40-kDa polyethylene glycol (PEG) polymer.[1]

The peptide component is a derivative of compstatin, a family of molecules known for their potent C3 inhibitory activity.[3] The specific amino acid sequence of each peptide is. A disulfide bridge between the two cysteine residues (Cys1 and Cys1) forms the cyclic structure, which is essential for its high binding affinity to C3.[13]

The PEGylation of the molecule is a critical design element. Conjugating the peptides to the 40-kDa PEG backbone serves multiple purposes: it significantly increases the molecule's hydrodynamic radius, which prolongs its circulating half-life by reducing renal clearance; it enhances the drug's stability in vivo; and it is intended to minimize immunogenicity, a potential concern for peptide-based therapies.[1] This sophisticated molecular architecture underpins its therapeutic efficacy and allows for practical dosing schedules in chronic diseases.

2.2. Formulations, Brand Nomenclature, and Manufacturer

Pegcetacoplan is developed and commercialized by Apellis Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company focused on complement-driven diseases.[9] For the systemic formulation of Pegcetacoplan, Apellis collaborates with

Swedish Orphan Biovitrum AB (Sobi), which holds the rights for co-development and commercialization outside of the United States.[19]

The drug is marketed under different brand names, which correspond to its distinct formulations, routes of administration, and therapeutic indications:

• Empaveli®: This brand is used for the systemic formulation, which is a 1080 mg/20 mL (54 mg/mL) solution for subcutaneous infusion. It is approved for the treatment of PNH and C3G/IC-MPGN in adults and, for the latter, in pediatric patients 12 years and older.[7]
• Syfovre®: This brand refers to the ophthalmic formulation, which is a 150 mg/mL solution intended for intravitreal injection. It is approved for the treatment of GA secondary to AMD, administered as a 15 mg (0.1 mL) dose.[4]
• Aspaveli®: This is the brand name under which the systemic formulation for PNH is marketed in the European Union.[4]

This branding strategy clearly delineates the two very different clinical applications and delivery methods of the same active substance, preventing potential confusion among healthcare providers in different specialties.

Table 1: Key Identifiers and Properties of Pegcetacoplan

Property	Value	Source Snippet(s)
DrugBank ID	DB16694	4
Type	Biotech, Other Biologics	4
Generic Name	Pegcetacoplan	4
Brand Names	Empaveli®, Syfovre®, Aspaveli®	4
Manufacturer	Apellis Pharmaceuticals, Inc.	9
CAS Number	2019171-69-6	5
UNII	TO3JYR3BOU	5
ATC Codes	L04AJ03 (Systemic), S01XA31 (Ophthalmic)	7
Chemical Formula	C1970​H3848​N50​O947​S4​	7
Molar Mass	~43520.10 g·mol−1	7
Compound Class	Peptide, Compstatin Analog	1

III. Pharmacology and Mechanism of Action

The therapeutic effect of Pegcetacoplan is derived from its targeted and potent inhibition of a central protein in the complement system. Understanding its mechanism requires a foundational knowledge of the complement cascade and the strategic advantage of intervening at an upstream juncture.

3.1. The Complement System: A Primer

The complement system is a complex network of over 30 proteins that acts as a primary effector arm of the innate immune system. Its functions include defense against pathogens, clearance of apoptotic cells and immune complexes, and bridging innate and adaptive immunity.[1] The system can be activated through three distinct pathways:

1. The Classical Pathway: Typically initiated by the binding of C1q to antigen-antibody complexes.
2. The Lectin Pathway: Activated when mannose-binding lectins or ficolins recognize specific carbohydrate patterns on microbial surfaces.
3. The Alternative Pathway: Characterized by a constant, low-level spontaneous activation of C3, which serves as an amplification loop for the other pathways.

Despite their different triggers, all three pathways converge at a single, critical event: the cleavage of the Complement C3 protein.[3] This cleavage is mediated by enzymes known as C3 convertases. C3 is split into two functionally distinct fragments:

• C3a: A small anaphylatoxin that promotes inflammation by recruiting and activating immune cells like mast cells and phagocytes.[14]
• C3b: A larger fragment that acts as a potent opsonin. It covalently binds to the surface of target cells (e.g., bacteria or damaged host cells), "tagging" them for destruction by phagocytes.[4] C3b is also an essential component of the C5 convertase, the enzyme that initiates the final, lytic phase of the cascade.

The generation of C3b leads to the formation of the Membrane Attack Complex (MAC), a pore-forming structure (composed of C5b-9) that inserts into the target cell membrane, causing osmotic lysis and cell death.[4] In diseases like PNH, uncontrolled complement activation leads to the destruction of the body's own red blood cells through both C3b-mediated opsonization and MAC-mediated lysis.

3.2. Proximal C3 Inhibition: A Novel Therapeutic Strategy

Pegcetacoplan's mechanism of action is defined as proximal complement inhibition, as it targets the cascade at its central convergence point, C3, which is upstream of the terminal pathway.[1] The drug's two compstatin-derived cyclic peptides bind with high affinity and specificity to both native C3 and its activated fragment, C3b.[1] This binding occurs within a shallow groove on the β-chain of the C3 molecule, which sterically hinders the ability of C3 convertases to access and cleave C3.[3]

By preventing the cleavage of C3, Pegcetacoplan exerts several profound effects:

• It blocks the generation of the inflammatory mediator C3a.[14]
• It prevents the deposition of the opsonin C3b onto cell surfaces, thereby inhibiting phagocytosis-mediated cell destruction.[4]
• It halts the amplification loop of the alternative pathway, which is dependent on C3b.[14]
• By preventing C3b formation, it also blocks the assembly of the C5 convertase, thereby preventing the activation of the entire downstream terminal pathway and the formation of the MAC.[16]

A key feature of this mechanism is its broad-spectrum inhibition. Because all three complement pathways rely on C3 cleavage to propagate their effects, Pegcetacoplan effectively regulates the entire complement system, regardless of the initial trigger.[14] This comprehensive control is the cornerstone of its therapeutic efficacy across different diseases.

3.3. Pharmacodynamic Effects

The pharmacodynamic effects of Pegcetacoplan are a direct reflection of its potent C3 inhibition and are measurable through various biomarkers. Administration of the drug leads to a rapid, dose-dependent, and sustained suppression of complement activity.

In studies involving intravenous administration to healthy volunteers, Pegcetacoplan produced an immediate and profound reduction in complement activity. Within one hour of infusion, levels of alternative pathway hemolytic activity (AH50) and the anaphylatoxin C3a were significantly decreased, demonstrating a rapid onset of action that could be beneficial in acute settings.[30]

In the context of PNH, the pharmacodynamic effects are observed through the normalization of key hematological markers. Treatment with Pegcetacoplan leads to a rapid and sustained decrease in lactate dehydrogenase (LDH), a marker of intravascular hemolysis, and a reduction in total bilirubin. Concurrently, levels of haptoglobin, which is consumed during hemolysis, increase toward normal.[3] These biochemical changes correlate directly with the clinical outcome of increased hemoglobin levels and reduced anemia.[6]

In nephrology, specifically C3G and IC-MPGN, the drug's effect is visualized directly at the site of pathology. The hallmark of these diseases is the excessive deposition of C3 fragments in the glomeruli of the kidney. Treatment with Pegcetacoplan leads to a substantial reduction and, in a majority of patients, complete clearance of glomerular C3c staining on repeat kidney biopsies. This histological evidence provides definitive proof of target engagement and is associated with clinical improvements in proteinuria and kidney function.[10]

In ophthalmology, for GA, the pharmacodynamic effect is localized within the eye. The mechanism is theorized to involve the inhibition of chronic, low-grade complement activation on the surface of retinal cells. By reducing the deposition of complement fragments and dampening the local inflammatory microenvironment, Pegcetacoplan is believed to slow the progressive death of retinal pigment epithelium (RPE) cells and photoreceptors that characterizes GA.[8]

3.4. Comparative Pharmacology: C3 vs. C5 Inhibition

The development of Pegcetacoplan was driven by the limitations of the previous standard of care in PNH, the C5 inhibitors eculizumab and ravulizumab. A comparison of their mechanisms reveals the fundamental advantage of proximal C3 inhibition.

C5 inhibitors act at the terminal end of the complement cascade. They bind to the C5 protein, preventing its cleavage into C5a and C5b. This effectively blocks the formation of the MAC and provides excellent control over intravascular hemolysis (IVH), the process of red blood cell lysis within blood vessels.[1] This control of IVH significantly reduces the risk of thrombosis and improves survival in PNH patients.

However, C5 inhibition leaves the upstream portion of the complement cascade completely intact. The alternative pathway continues to generate C3b, which accumulates on the surface of PNH red blood cells. These C3b-opsonized cells are then recognized and cleared by macrophages in the reticuloendothelial system, primarily in the liver and spleen. This process, known as extravascular hemolysis (EVH), persists in patients treated with C5 inhibitors.[1] As a result, a significant proportion of patients on C5 inhibitors, despite having controlled IVH, remain anemic, fatigued, and may continue to require blood transfusions.[1]

This unmet medical need was the primary driver for developing an upstream inhibitor. Pegcetacoplan, by blocking C3, offers a more comprehensive solution. It not only prevents the downstream formation of the MAC, thereby controlling IVH, but it also stops the generation of C3b, thus preventing the opsonization that drives EVH.[3] This dual control of both major hemolytic pathways is the key pharmacological distinction and clinical advantage of Pegcetacoplan over C5 inhibitors in the management of PNH. This ability to address a well-defined limitation of a previous blockbuster drug class validated the C3 target and represented a paradigm shift in the therapeutic strategy for complement-mediated diseases. The success of this approach in PNH paved the way for its exploration and eventual approval in other diseases where C3 dysregulation is a central pathogenic driver, such as GA and C3G, demonstrating a breadth of applicability that is a direct consequence of its upstream mechanism of action.

IV. Pharmacokinetic Profile

The pharmacokinetic (PK) properties of Pegcetacoplan are highly dependent on its route of administration. The drug has been meticulously formulated and studied for two distinct delivery methods—subcutaneous infusion for systemic diseases and intravitreal injection for localized ocular disease—resulting in two very different PK profiles tailored to specific therapeutic goals.

4.1. Subcutaneous Administration (PNH, C3G/IC-MPGN)

For systemic indications like PNH and C3G/IC-MPGN, the goal is to achieve and maintain high, stable serum concentrations of the drug to ensure continuous, body-wide inhibition of the complement system.

• Absorption: Following subcutaneous injection, Pegcetacoplan is absorbed slowly and gradually into the systemic circulation. The median time to reach maximum serum concentration (Tmax) is approximately 4.5 to 6.0 days (108 to 144 hours).[4] This slow absorption profile contributes to stable drug levels between doses.
• Distribution: Pegcetacoplan has a relatively small mean volume of distribution of approximately 3.9 liters in patients with PNH, suggesting that it is primarily confined to the vascular and interstitial compartments.[4]
• Steady State: With the recommended twice-weekly dosing regimen of 1,080 mg, steady-state serum concentrations are achieved in approximately 4 to 6 weeks.[7] At steady state, the average trough serum concentrations are substantial, ranging from 655 to 706 µg/mL, levels sufficient to maintain robust C3 inhibition.[7]
• Metabolism and Elimination: As a pegylated peptide, Pegcetacoplan is presumed to be broken down into smaller peptides and constituent amino acids through general catabolic pathways, rather than being metabolized by cytochrome P450 enzymes.[4] The mean clearance rate is low, at approximately 0.015 L/hour (0.37 L/day).[5] This slow clearance, combined with its large size due to PEGylation, results in a long median effective elimination half-life of approximately 8.0 days in PNH patients.[7] Studies conducted in cynomolgus monkeys indicated that the peptide component is primarily eliminated via urinary excretion.[4] Importantly, pharmacokinetic analyses have shown that key parameters are not significantly affected by patient demographics such as sex, age, and race, nor by baseline renal or hepatic function, obviating the need for dose adjustments in these populations.[29]

4.2. Intravitreal Administration (GA)

For the treatment of GA, the therapeutic objective is fundamentally different: to achieve a high, sustained drug concentration locally within the eye (specifically, the vitreous humor) while minimizing systemic exposure and its associated risks, such as systemic immunosuppression.

• Systemic Exposure: Following a 15 mg intravitreal injection, only very low concentrations of Pegcetacoplan are detected in the systemic circulation. After 24 months of treatment, the mean steady-state trough serum concentrations were approximately 0.9061 µg/mL for patients on an every-other-month dosing schedule.[12] This level is nearly three orders of magnitude lower than the trough concentrations seen with systemic administration, illustrating the success of the localized delivery approach in limiting systemic exposure.
• Pharmacodynamics in Vitreous Humor: The clinical efficacy in GA is driven by the local drug concentration within the eye. A population PK/pharmacodynamic (PD) model was developed using data from the pivotal GA clinical trials. This model established a direct quantitative relationship between the concentration of Pegcetacoplan in the vitreous humor and the therapeutic effect. Specifically, the analysis found a 2.6% reduction in the rate of GA lesion growth for every unit increase in the log-transformed vitreous concentration of the drug.[36] This finding confirms that the local pharmacokinetics are the primary determinant of the drug's activity in the eye.
• Immunogenicity: The long-term administration of a pegylated peptide can elicit an immune response. In the 24-month GA trials, the incidence of anti-drug antibodies (ADAs) was monitored. The development of antibodies against the pegcetacoplan peptide itself was relatively low, occurring in 2.5% to 4.3% of patients. However, the incidence of antibodies against the PEG moiety was more substantial, observed in 10.2% to 14.1% of patients.[12] While the clinical impact of these anti-PEG antibodies has not been fully elucidated in the context of Pegcetacoplan, their presence is a notable finding that warrants continued monitoring in long-term use, as they could potentially alter the drug's PK profile or safety.

The dual pharmacokinetic profiles of Pegcetacoplan highlight a sophisticated approach to drug development. The same active molecule has been adapted through formulation and route of administration to serve two disparate therapeutic purposes. The systemic formulation leverages the long half-life afforded by PEGylation to provide the sustained, high-level complement blockade necessary for diseases like PNH. In contrast, the ophthalmic formulation uses the principle of localized delivery to concentrate the drug at the site of pathology in GA, thereby maximizing local efficacy while minimizing the potential for systemic side effects. This tailored approach is a testament to the versatility of the molecule and the strategic design of its clinical development program.

V. Clinical Evidence and Therapeutic Applications

The clinical development program for Pegcetacoplan has been extensive, spanning multiple therapeutic areas and establishing its efficacy and safety in several rare and serious diseases. The pivotal trials for each approved indication have provided robust evidence supporting its use and have, in some cases, redefined the standard of care.

5.1. Paroxysmal Nocturnal Hemoglobinuria (PNH)

In PNH, Pegcetacoplan was studied in two key populations: patients who remained anemic despite treatment with C5 inhibitors and patients who were new to complement inhibitor therapy.

5.1.1. Efficacy in C5-Inhibitor-Experienced Patients: The PEGASUS Trial (NCT03500549)

The PEGASUS study was a landmark Phase 3 trial designed to directly challenge the established standard of care for PNH. It was a randomized, open-label, active-comparator trial that enrolled 80 adult PNH patients who, despite being on a stable dose of the C5 inhibitor eculizumab, remained significantly anemic with hemoglobin levels below 10.5 g/dL.[37] After a 4-week run-in period where patients received both drugs, they were randomized 1:1 to receive either Pegcetacoplan monotherapy (1,080 mg subcutaneously twice weekly) or to continue their eculizumab regimen for 16 weeks.[31]

The trial met its primary endpoint with statistical significance, demonstrating the clear superiority of Pegcetacoplan. At week 16, patients in the Pegcetacoplan arm had an adjusted mean increase in hemoglobin of 2.4 g/dL from baseline. In stark contrast, patients continuing on eculizumab experienced a mean decrease of 1.5 g/dL. The difference between the two groups was a clinically profound 3.8 g/dL (p<0.0001).[31]

The superiority of Pegcetacoplan was further reinforced across all key secondary endpoints. An overwhelming majority of patients on Pegcetacoplan (85%) became transfusion-free during the 16-week period, compared to only 15% of those on eculizumab. Markers of hemolysis also showed significant improvement, with 71% of Pegcetacoplan-treated patients achieving normalization of LDH levels versus just 15% in the eculizumab group. Furthermore, the hematological benefits translated into a meaningful improvement in patient quality of life, with 73% of patients on Pegcetacoplan reporting a clinically significant reduction in fatigue, compared to 0% in the eculizumab group.[31] The PEGASUS trial provided unequivocal evidence that by controlling both intravascular and extravascular hemolysis, proximal C3 inhibition with Pegcetacoplan could effectively resolve the persistent anemia that limited the efficacy of C5 inhibitors.

5.1.2. Efficacy in Complement-Naïve Patients: The PRINCE Trial (NCT04085601)

To establish its role as a first-line therapy, the PRINCE trial was conducted. This Phase 3, randomized, open-label study compared Pegcetacoplan to standard of care (which excluded complement inhibitors) in 53 adult PNH patients who had not previously been treated with a complement inhibitor.[6]

The results were compelling. Pegcetacoplan demonstrated superiority over standard of care on both co-primary endpoints at 26 weeks. For the endpoint of hemoglobin stabilization (defined as avoiding a >1 g/dL decrease in hemoglobin without transfusions), 86% of patients in the Pegcetacoplan arm achieved this outcome, compared to 0% in the standard of care arm. For the second co-primary endpoint, Pegcetacoplan led to a significantly greater reduction in LDH levels from baseline compared to the control group.[24] These results confirmed that Pegcetacoplan is a highly effective initial therapy for PNH, capable of rapidly controlling hemolysis and stabilizing hemoglobin levels in patients new to treatment.

5.1.3. Long-Term Safety and Efficacy (APL2-307 Extension Study, NCT03531255)

The long-term durability of Pegcetacoplan's effects was assessed in the APL2-307 open-label extension study, which enrolled patients who had completed previous PNH trials.[44] Post-hoc analysis of data for up to three years of continuous treatment demonstrated that the clinical benefits were robust and sustained. Mean hemoglobin levels were maintained at approximately 11.6 g/dL, and LDH levels remained controlled below the upper limit of normal. The majority of patients who had been transfusion-dependent prior to the studies remained transfusion-free long-term (52% from the PEGASUS cohort and 67% from the PRINCE cohort).[44] The safety profile remained consistent over this extended period, with no new safety signals emerging. Notably, in this long-term analysis, there were no reported cases of meningococcal infection, suggesting that the REMS and mandatory vaccination protocol are effective risk mitigation strategies.[44]

Table 2: Summary of Pivotal Phase 3 Trial Results for Paroxysmal Nocturnal Hemoglobinuria

Endpoint	PEGASUS Trial (Pegcetacoplan vs. Eculizumab)	PRINCE Trial (Pegcetacoplan vs. Standard of Care)	Source Snippet(s)
Patient Population	Adults with PNH and persistent anemia (Hb <10.5 g/dL) despite stable eculizumab treatment (n=80)	Complement inhibitor-naïve adults with PNH (n=53)	37
Primary Endpoint	Change in Hemoglobin at Week 16: Superiority demonstrated. Adjusted mean difference of +3.8 g/dL in favor of Pegcetacoplan (p<0.0001).	Hemoglobin Stabilization at Week 26: Superiority demonstrated. 86% in Pegcetacoplan arm vs. 0% in control arm.	31
Co-Primary Endpoint	N/A	Change in LDH from Baseline at Week 26: Superiority demonstrated. Significant reduction in LDH with Pegcetacoplan vs. control.	24
Transfusion Avoidance	85% of Pegcetacoplan patients were transfusion-free vs. 15% of eculizumab patients over 16 weeks.	~91% of Pegcetacoplan patients were transfusion-free vs. 6% of control patients over 26 weeks.	24
LDH Normalization	71% of Pegcetacoplan patients achieved LDH normalization vs. 15% of eculizumab patients.	N/A (LDH reduction was a primary endpoint)	31
FACIT-Fatigue Score	73% of Pegcetacoplan patients had a clinically meaningful improvement vs. 0% of eculizumab patients.	Significant improvement from baseline observed.	31

5.2. Geographic Atrophy (GA) Secondary to AMD

The development of Pegcetacoplan for GA was a pioneering effort, as there were no approved treatments for this advanced form of dry age-related macular degeneration, a leading cause of irreversible blindness.

5.2.1. Pivotal Phase 3 Evidence: The OAKS (NCT03525613) and DERBY (NCT03525600) Trials

The foundation for the GA approval was a pair of large, parallel Phase 3 trials, OAKS and DERBY. These multicenter, randomized, double-masked, sham-controlled studies enrolled a broad population of over 1,250 patients with GA.[47] Participants were randomized to receive intravitreal injections of Pegcetacoplan 15 mg either monthly (PM) or every other month (PEOM), or to receive sham injections on the same schedules, for a duration of 24 months.[28]

The primary endpoint for both studies was anatomical: the change in the total area of GA lesions from baseline, as measured by fundus autofluorescence. The results showed that Pegcetacoplan significantly slowed the physical progression of the disease. In pooled 24-month data, monthly Pegcetacoplan reduced the rate of lesion growth by 22% compared to sham. The every-other-month regimen showed a reduction of 18-19%.[28] A key observation was that the treatment effect appeared to increase over time, with the most pronounced separation from the sham group occurring in the final six months of the study (months 18-24).[48]

However, the trials presented a complex picture regarding functional vision. Despite the clear anatomical benefit, the studies failed to meet their key secondary endpoints related to visual function over the 24-month period. There was no statistically significant difference between the Pegcetacoplan and sham groups in preserving best-corrected visual acuity (BCVA), reading speed, or functional measures from microperimetry.[52] This disconnect between the anatomical outcome (slowing lesion growth) and the short-term functional outcomes became a central point of debate among clinicians and regulators.

5.2.2. Long-Term Effects: The GALE Extension Study (NCT04770545)

To assess the long-term impact of treatment, eligible patients from OAKS and DERBY were enrolled in the GALE open-label extension study.[49] The results from GALE showed that the anatomical benefit not only persisted but continued to increase. When compared against a projected sham group, continuous treatment with monthly Pegcetacoplan reduced GA lesion growth by up to 35% between months 24 and 36. The effect was even more pronounced in patients with nonsubfoveal lesions (lesions not yet affecting the center of vision), where the reduction reached up to 45%.[49]

Crucially, the GALE study provided the first evidence of a potential long-term functional benefit. A prespecified analysis of microperimetry data, which maps visual sensitivity across the retina, was conducted at 36 months. This analysis showed that patients who had received continuous monthly treatment developed significantly fewer new scotomatous points (new areas of vision loss) compared to patients who had been in the sham group for 24 months before crossing over to active treatment (p=0.0156).[50] This finding suggested that the sustained slowing of anatomical damage eventually translates into a measurable preservation of visual function, though this benefit may take longer than two years to become apparent.

Table 3: Summary of Pivotal Phase 3 Trial Results for Geographic Atrophy

Endpoint	OAKS & DERBY Trials (at 24 Months)	GALE Extension Study (at 36 Months)	Source Snippet(s)
Primary Endpoint: % Reduction in GA Lesion Growth vs. Sham	Monthly: 22% Every-Other-Month: 18-19% (Effect increased over time)	Monthly: up to 35% vs. projected sham Every-Other-Month: up to 24% vs. projected sham (Effect continued to increase)	47
Functional Endpoint: Best-Corrected Visual Acuity (BCVA)	No statistically significant benefit demonstrated compared to sham.	N/A (Not the primary focus of long-term analysis)	52
Functional Endpoint: Microperimetry (New Scotomatous Points)	No statistically significant benefit demonstrated compared to sham.	Statistically significant benefit observed with continuous monthly treatment vs. sham crossover group (p=0.0156).	50

5.3. C3 Glomerulopathy (C3G) and IC-MPGN

Pegcetacoplan was investigated as a targeted therapy for these rare and severe kidney diseases, which are characterized by the dysregulation of the alternative complement pathway and deposition of C3 in the glomeruli.

5.3.1. Pivotal Phase 3 Evidence: The VALIANT Trial (NCT05067127)

The VALIANT trial was a robust Phase 3, randomized, placebo-controlled, double-blind study that enrolled 124 patients aged 12 years and older with either C3G or IC-MPGN. The study population was diverse, including patients with native kidneys and those who had disease recurrence after a kidney transplant.[9] Patients received subcutaneous Pegcetacoplan or placebo twice weekly for 26 weeks, with the option to enter a subsequent open-label phase.[57]

The trial was a resounding success, meeting its primary endpoint and all key secondary endpoints.

• Primary Endpoint (Proteinuria): At 26 weeks, patients treated with Pegcetacoplan had a statistically significant and clinically meaningful 68% reduction in proteinuria (as measured by the urine protein-to-creatinine ratio, UPCR) compared to the placebo group (p<0.0001).[10] This benefit was observed as early as week 4 and was shown to be sustained at the one-year mark in the open-label portion of the study.[33]
• Key Secondary Endpoint (Kidney Function): Treatment with Pegcetacoplan led to the stabilization of kidney function. This was measured by the estimated glomerular filtration rate (eGFR), where a clinically meaningful difference in favor of Pegcetacoplan was observed compared to the decline seen in the placebo group.[10]
• Key Secondary Endpoint (Histology): The trial demonstrated a profound effect on the underlying pathology of the disease. On repeat kidney biopsies, a remarkable 71% of patients in the Pegcetacoplan arm achieved complete clearance of C3c staining in their glomeruli, indicating that the drug was effectively halting the pathogenic complement deposition.[10]

The efficacy of Pegcetacoplan was consistent across all analyzed subgroups, including patients with C3G versus IC-MPGN, adolescents versus adults, and those with native versus post-transplant kidneys.[10] The VALIANT trial provided the first high-level evidence for a therapy that could modify the course of these devastating kidney diseases by addressing their root cause.

Table 4: Summary of Pivotal Phase 3 Trial Results for C3G and IC-MPGN (VALIANT)

Endpoint	Pegcetacoplan vs. Placebo (at 26 Weeks)	p-value	Source Snippet(s)
Primary Endpoint: % Reduction in Proteinuria (UPCR)	68% greater reduction with Pegcetacoplan.	<0.0001	10
Secondary Endpoint: eGFR Stabilization	Statistically significant stabilization of kidney function with Pegcetacoplan vs. decline with placebo.	Nominal p=0.03	10
Secondary Endpoint: % of Patients with C3c Clearance	71% of Pegcetacoplan patients achieved complete clearance of C3c staining.	Nominal p<0.0001 for 2-order magnitude reduction	10

VI. Safety and Tolerability Profile

The safety profile of Pegcetacoplan is well-characterized and is intrinsically linked to its mechanism of action. While generally well-tolerated, its potent inhibition of a central immune pathway necessitates specific monitoring and risk mitigation strategies. The adverse event profile differs significantly between its systemic and intravitreal formulations.

6.1. Common and Serious Adverse Events

• Systemic Administration (Empaveli® for PNH and C3G/IC-MPGN): The most frequently reported adverse reactions are associated with the subcutaneous infusion and the systemic effects of complement inhibition. Common adverse events (occurring in ≥10% of patients) include injection-site reactions (such as redness, pain, swelling, or itching), various infections (most commonly upper respiratory tract infections and nasopharyngitis), diarrhea, abdominal pain, headache, fatigue, and cough.[2] Hypokalemia (low potassium levels) has also been noted as a common metabolic abnormality.[2] The most common serious adverse reactions identified in PNH clinical trials were hemolysis (typically breakthrough hemolysis associated with triggers like infection) and sepsis.[62]
• Intravitreal Administration (Syfovre® for GA): The adverse event profile for the ophthalmic formulation is dominated by ocular events. These can be categorized into events related to the injection procedure itself and those related to the drug's pharmacology. Procedure-related events include conjunctival hemorrhage, eye pain, vitreous floaters, and transient increases in intraocular pressure (IOP) immediately following injection.[23] Drug-specific adverse events are discussed in more detail below.

6.2. Boxed Warning: Risk of Serious Infections

Pegcetacoplan carries a Boxed Warning from the FDA, the most serious level of warning, regarding the risk of life-threatening infections caused by encapsulated bacteria.[2] This risk is a direct and predictable consequence of its mechanism. The complement system, particularly C3b-mediated opsonization, is a primary defense mechanism against bacteria with polysaccharide capsules, such as

Streptococcus pneumoniae, Neisseria meningitidis (meningococcus), and Haemophilus influenzae type B (Hib).[1] By inhibiting C3, Pegcetacoplan significantly impairs the body's ability to fight these specific pathogens.

To mitigate this serious risk, a stringent safety protocol is mandated:

1. Vaccination: Patients must be vaccinated against meningococcal (serogroups A, C, W, Y, and B), pneumococcal, and Hib bacteria. These vaccinations should be administered at least two weeks before starting Pegcetacoplan therapy to allow for an adequate immune response.[2]
2. Prophylaxis: If treatment must be initiated urgently before the two-week post-vaccination window is complete, patients should receive prophylactic antibacterial drug therapy.[35]
3. REMS Program: Due to this risk, Pegcetacoplan is available only through a restricted distribution program known as a Risk Evaluation and Mitigation Strategy (REMS). Under the EMPAVELI REMS, prescribers must enroll in the program, counsel patients about the infection risk, and ensure their vaccination status is up to date. Patients are provided with a Patient Safety Card that they must carry at all times, which details the signs and symptoms of meningitis and other serious infections and instructs them to seek immediate medical care if they occur.[11]

6.3. Indication-Specific Safety Concerns

Beyond the systemic risk of infection, there are important safety considerations specific to each indication.

• Geographic Atrophy (Ocular Safety):
• Neovascular (Wet) AMD: A significant finding from the GA clinical trials was an increased rate of conversion to exudative or neovascular AMD in eyes treated with Syfovre. At 24 months, the incidence was 12% in the monthly treatment group and 7% in the every-other-month group, compared to only 3% in the sham group.[23] This requires diligent monitoring of patients for signs of neovascularization, which may necessitate separate treatment with anti-VEGF therapy.
• Retinal Vasculitis and Vascular Occlusion: Post-marketing, rare but very serious cases of occlusive retinal vasculitis, often accompanied by severe intraocular inflammation, were reported. These events can manifest even after the first injection and have led to severe and irreversible vision loss in some cases.[52] This emergent safety concern has prompted heightened vigilance in the ophthalmology community and is a critical factor in the risk-benefit assessment for GA patients.
• Intraocular Inflammation and Endophthalmitis: As with all intravitreal therapies, Syfovre carries risks of non-infectious intraocular inflammation (e.g., vitritis, uveitis) and infectious endophthalmitis. Proper aseptic injection technique is critical to minimize these risks.[23]
• Paroxysmal Nocturnal Hemoglobinuria (Discontinuation Risk):
• Due to the rapid return of complement activity upon cessation of therapy, abrupt discontinuation of Empaveli can lead to a sudden and severe recurrence of hemolysis. This can manifest as a sharp rise in LDH levels, fatigue, dark urine, and an increased risk of thrombosis. Therefore, patients who stop taking the drug must be closely monitored for signs and symptoms of hemolysis for at least 8 weeks.[11]

Table 5: Summary of Common and Serious Adverse Events by Indication

Adverse Event Category	PNH & C3G/IC-MPGN (Subcutaneous - Empaveli®)	Geographic Atrophy (Intravitreal - Syfovre®)	Source Snippet(s)
Common Administration-Site Reactions	Injection-site reactions (redness, pain, swelling, itching)	Conjunctival hemorrhage, eye pain, vitreous floaters, increased IOP	11
Common Systemic AEs (≥10%)	Infections (URI, nasopharyngitis), diarrhea, abdominal pain, headache, fatigue, cough	Minimal systemic AEs due to low exposure	11
Serious Infections (Boxed Warning)	High Risk: Life-threatening infections from encapsulated bacteria (N. meningitidis, S. pneumoniae, H. influenzae). Requires REMS and vaccination.	Low Risk: Systemic immunosuppression is not a primary concern due to localized delivery, but caution is still advised.	2
Indication-Specific Serious AEs	Breakthrough hemolysis (often with triggers), sepsis, thrombosis (if discontinued abruptly)	Neovascular (wet) AMD, occlusive retinal vasculitis, endophthalmitis, retinal detachment, intraocular inflammation	11

6.4. Contraindications and Special Populations

• Contraindications: Systemic Pegcetacoplan is contraindicated in patients with an unresolved serious infection caused by encapsulated bacteria and in patients who are not currently vaccinated against these organisms (unless the benefits of immediate treatment outweigh the risks and prophylactic antibiotics are administered).[24] The ophthalmic formulation, Syfovre, is additionally contraindicated in patients with active ocular or periocular infections, or with active intraocular inflammation.[23] Hypersensitivity to pegcetacoplan or any of its excipients is a contraindication for all formulations.
• Pregnancy and Lactation: There are no adequate and well-controlled studies in pregnant women. Based on its mechanism of action, Pegcetacoplan may cause fetal harm. Therefore, females of reproductive potential are advised to use effective contraception during treatment and for 40 days following the final dose.[7] It is not known whether Pegcetacoplan is excreted in human milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment and for 40 days after the last dose.[27]

VII. Regulatory Landscape and Clinical Practice

The regulatory journey of Pegcetacoplan has been notable for its successes across multiple therapeutic areas and for a significant divergence in opinion between major global health authorities on one of its key indications. This landscape shapes its availability and use in clinical practice.

7.1. Global Regulatory Approvals and Divergence

• U.S. Food and Drug Administration (FDA): The FDA has granted approval for Pegcetacoplan in all three of its major indications, often with expedited review pathways reflecting the high unmet need in these patient populations.
• Paroxysmal Nocturnal Hemoglobinuria (PNH): Empaveli® was approved on May 14, 2021, for the treatment of adults with PNH.[4] The application benefited from Fast Track, Priority Review, and Orphan Drug designations, underscoring the disease's severity and the drug's potential to improve upon existing therapies.[37]
• Geographic Atrophy (GA): Syfovre® received a landmark approval on February 17, 2023, becoming the first and only treatment for GA secondary to AMD.[4] This decision was based on the OAKS and DERBY trials demonstrating a reduction in the rate of lesion growth.
• C3 Glomerulopathy (C3G) and IC-MPGN: Empaveli®'s label was expanded on July 28, 2025 (Note: this is a future date found in the source material, likely a typo for 2024 or 2023, but reported as written), to include the treatment of C3G and primary IC-MPGN in patients aged 12 years and older.[9] This application also received Priority Review.[67]
• European Medicines Agency (EMA): The EMA's evaluation has led to different outcomes, particularly for the GA indication.
• Paroxysmal Nocturnal Hemoglobinuria (PNH): Aspaveli® was approved in the European Union in December 2021. Initially, the indication was for adult PNH patients who remained anemic after at least three months of treatment with a C5 inhibitor.[19] This label was later expanded to include treatment-naïve patients, aligning more closely with the broader U.S. indication.[41]
• Geographic Atrophy (GA): In a significant regulatory divergence, the marketing authorisation application for Syfovre® was withdrawn by Apellis on October 4, 2024. This action followed a recommendation for refusal from the EMA's Committee for Medicinal Products for Human Use (CHMP).[8] The EMA's rationale was that, while the drug did slow the anatomical progression of GA lesions, this effect was not considered to translate into a "clinically meaningful benefit" for patients' visual function within the timeframe of the studies. The agency concluded that the demonstrated benefits did not outweigh the potential risks, including intraocular inflammation and the development of neovascular AMD.[8]

This split decision between the FDA and EMA on the GA indication is a critical case study in modern drug regulation. It highlights differing philosophies on the value and acceptability of surrogate endpoints (like lesion growth rate) versus direct functional endpoints (like visual acuity). The FDA, in the absence of any other treatment, appeared to weigh the anatomical benefit as sufficient for approval, potentially with the expectation that functional benefits might emerge over a longer timeframe. The EMA, conversely, applied a stricter standard, requiring a demonstrated impact on how patients see or function before it would consider the risk-benefit balance to be positive. This divergence creates significant implications for global drug development strategies and results in differential access to therapy for patients depending on their geographic location.

7.2. Dosing, Administration, and Risk Management

The practical use of Pegcetacoplan is highly specific to the formulation and indication.

• Empaveli® (for PNH, C3G/IC-MPGN):
• Dosage: The standard recommended dose is 1,080 mg administered subcutaneously twice weekly.[2] For PNH patients who experience breakthrough hemolysis (indicated by LDH levels greater than twice the upper limit of normal), the dosing frequency can be increased to 1,080 mg every three days.[21]
• Administration: The drug is administered as a subcutaneous infusion using either a commercially available infusion pump or the on-body Empaveli Injector. The infusion typically takes approximately 30 minutes if using two infusion sites or 60 minutes if using one site. Patients or their caregivers can be trained to perform the administration at home, offering a significant convenience advantage over intravenous therapies.[11]
• Syfovre® (for GA):
• Dosage: The recommended dose is 15 mg (in a 0.1 mL volume) administered by intravitreal injection into the affected eye.[23]
• Frequency: The dosing schedule is flexible, allowing for administration once every 25 to 60 days. This flexibility enables physicians to tailor the treatment frequency based on the patient's disease activity, risk factors, and tolerance.[23]
• Administration: Intravitreal injections are a medical procedure that must be performed by a qualified physician (typically a retina specialist) under strict aseptic conditions to minimize the risk of infection and other complications.[23]

VIII. Conclusion and Future Directions

Pegcetacoplan has firmly established itself as a transformative therapeutic agent and the vanguard of a new class of proximal complement inhibitors. By targeting C3, the central hub of the complement cascade, it has validated a therapeutic strategy that offers broader and more comprehensive control of complement-mediated pathology than was previously possible with terminal pathway inhibitors. Its successful development and approval across three distinct and complex disease areas—hematology, ophthalmology, and nephrology—underscore the fundamental role of C3 dysregulation in a wide spectrum of human diseases.

In Paroxysmal Nocturnal Hemoglobinuria, Pegcetacoplan has redefined the standard of care. By effectively controlling both intravascular and extravascular hemolysis, it directly addressed the significant unmet need of persistent anemia in patients treated with C5 inhibitors, leading to superior hematological outcomes and improvements in quality of life. The PRINCE trial further established its efficacy as a potent first-line therapy, offering a comprehensive treatment option for all adult patients with PNH.

In Geographic Atrophy, Pegcetacoplan broke new ground as the first-ever approved therapy, offering hope to millions at risk of irreversible blindness. While its approval was based on a clear anatomical benefit of slowing lesion progression, the initial lack of a corresponding functional benefit and the subsequent regulatory divergence between the FDA and EMA have created a complex clinical landscape. The emerging long-term data from the GALE study, suggesting a preservation of visual function over 36 months, may be crucial in clarifying its ultimate value and resolving this debate. Continued real-world safety monitoring, particularly regarding rare events like retinal vasculitis, will also be essential.

For the rare kidney diseases C3G and IC-MPGN, Pegcetacoplan represents a breakthrough. The robust and consistent results of the VALIANT trial—demonstrating significant reductions in proteinuria, stabilization of kidney function, and clearance of pathogenic C3 deposits—position it as the first truly disease-modifying therapy for these conditions, with the potential to alter their natural history and prevent progression to end-stage kidney disease.

The journey of Pegcetacoplan is far from over. Its mechanism of action holds promise for a range of other complement-mediated disorders, and clinical development is ongoing. Active trials are exploring its utility in conditions such as IgA nephropathy and lupus nephritis, which could further expand its therapeutic reach.[1] The PIONEER study in pediatric PNH is an important next step to extend its benefits to younger patients.[73] The long-term safety and efficacy data across all indications will continue to refine our understanding of its risk-benefit profile and optimal use. In conclusion, Pegcetacoplan is more than a single successful drug; it is a proof-of-concept for the power of proximal complement inhibition, heralding a new era in the treatment of complement-driven diseases.

Works cited

1. What is the therapeutic class of Pegcetacoplan? - Patsnap Synapse, accessed August 15, 2025, https://synapse.patsnap.com/article/what-is-the-therapeutic-class-of-pegcetacoplan
2. Pegcetacoplan - LiverTox - NCBI Bookshelf, accessed August 15, 2025, https://www.ncbi.nlm.nih.gov/books/NBK605496/
3. Pegcetacoplan for paroxysmal nocturnal hemoglobinuria - American Society of Hematology, accessed August 15, 2025, https://ashpublications.org/blood/article/139/23/3361/484521/Pegcetacoplan-for-paroxysmal-nocturnal
4. Pegcetacoplan: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed August 15, 2025, https://go.drugbank.com/drugs/DB16694
5. Pegcetacoplan - PubChem, accessed August 15, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Pegcetacoplan
6. Three Years On: The Role of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) since Its Initial Approval - MDPI, accessed August 15, 2025, https://www.mdpi.com/1422-0067/25/16/8698
7. Pegcetacoplan - Wikipedia, accessed August 15, 2025, https://en.wikipedia.org/wiki/Pegcetacoplan
8. Syfovre | European Medicines Agency (EMA), accessed August 15, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/syfovre
9. FDA Approves Apellis' EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older, accessed August 15, 2025, https://investors.apellis.com/news-releases/news-release-details/fda-approves-apellis-empavelir-pegcetacoplan-first-c3g-and
10. FDA Approves Pegcetacoplan for Rare Kidney Diseases C3G, Primary IC-MPGN in Patients 12 and Older - American Journal of Managed Care, accessed August 15, 2025, https://www.ajmc.com/view/fda-approves-pegcetacoplan-for-rare-kidney-diseases-c3g-primary-ic-mpgn-in-patients-12-and-older
11. Pegcetacoplan: Uses, Dosage, Side Effects, Warnings - Drugs.com, accessed August 15, 2025, https://www.drugs.com/pegcetacoplan.html
12. APPLICATION NUMBER: - 217171Orig1s000 CLINICAL PHARMACOLOGY REVIEW(S) - accessdata.fda.gov, accessed August 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217171Orig1s000ClinPharmR.pdf
13. pegcetacoplan | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 15, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13826
14. What is the mechanism of action of Pegcetacoplan? - Patsnap Synapse, accessed August 15, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-action-of-pegcetacoplan
15. What is the mechanism of Pegcetacoplan? - Patsnap Synapse, accessed August 15, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-pegcetacoplan
16. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria - PMC - PubMed Central, accessed August 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11652457/
17. Pegcetacoplan by Apellis Pharmaceuticals for IgA Nephropathy (Berger's Disease): Likelihood of Approval, accessed August 15, 2025, https://www.pharmaceutical-technology.com/data-insights/pegcetacoplan-apellis-pharmaceuticals-iga-nephropathy-berger-s-disease-likelihood-of-approval/
18. FDA Approves Pegcetacoplan Injector for Paroxysmal Nocturnal Hemoglobinuria, accessed August 15, 2025, https://www.cancernetwork.com/view/fda-approves-pegcetacoplan-injector-for-paroxysmal-nocturnal-hemoglobinuria
19. Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH, accessed August 15, 2025, https://investors.apellis.com/news-releases/news-release-details/apellis-and-sobi-announce-eu-approval-aspavelir-pegcetacoplan
20. Pegcetacoplan (Empaveli™) - Independence Blue Cross, accessed August 15, 2025, https://www.ibx.com/documents/35221/56638/empaveli.pdf
21. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EMPAVELI safely and effe - Apellis Pharmaceuticals, accessed August 15, 2025, https://pi.apellis.com/files/PI_Empaveli.pdf
22. Pegcetacoplan - brand name list from Drugs.com, accessed August 15, 2025, https://www.drugs.com/ingredient/pegcetacoplan.html
23. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYFOVRE safely and effec - Apellis Pharmaceuticals, accessed August 15, 2025, https://pi.apellis.com/files/PI_Syfovre.pdf
24. Aspaveli | European Medicines Agency (EMA), accessed August 15, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/aspaveli
25. en.wikipedia.org, accessed August 15, 2025, https://en.wikipedia.org/wiki/Pegcetacoplan#:~:text=Pegcetacoplan%2C%20sold%20under%20the%20brand,geographic%20atrophy%20of%20the%20retina.
26. CAS No : 2019171-69-6 | Product Name : Pegcetacoplan - API - Pharmaffiliates, accessed August 15, 2025, https://www.pharmaffiliates.com/en/2019171-69-6-pegcetacoplan-api-pa163730000.html
27. Pegcetacoplan - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed August 15, 2025, https://www.ncbi.nlm.nih.gov/sites/books/n/lactmed/pegcetacoplan/
28. Use of Pegcetacoplan in the treatment of geographic atrophy (GA) - NJRetina, accessed August 15, 2025, https://www.njretina.com/wp-content/uploads/2022/10/NJR_Newsletter_OCTOBER_2022_WEB_m1.pdf
29. Full article: Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria - Taylor & Francis Online, accessed August 15, 2025, https://www.tandfonline.com/doi/full/10.1080/17474086.2024.2440101
30. The Pharmacokinetics, Pharmacodynamics, and Safety of ..., accessed August 15, 2025, https://ashpublications.org/blood/article/138/Supplement%201/4304/481514/The-Pharmacokinetics-Pharmacodynamics-and-Safety
31. New Pivotal Data Demonstrate Superiority of Apellis' Pegcetacoplan ..., accessed August 15, 2025, https://investors.apellis.com/news-releases/news-release-details/new-pivotal-data-demonstrate-superiority-apellis-pegcetacoplan
32. Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects. | ClinicalTrials.gov, accessed August 15, 2025, https://clinicaltrials.gov/study/NCT02588833?term=pegcetacoplan&rank=8&tab=results
33. Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN - Apellis Pharmaceuticals, Inc., accessed August 15, 2025, https://investors.apellis.com/news-releases/news-release-details/pivotal-valiant-results-presented-kidney-week-highlight-strength
34. Expert Perspectives on VALIANT: Trial Design and Key Results - HCPLive, accessed August 15, 2025, https://www.hcplive.com/view/expert-perspectives-on-valiant-trial-design-and-key-results
35. Pegcetacoplan Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 15, 2025, https://www.drugs.com/dosage/pegcetacoplan.html
36. Pharmacokinetic/pharmacodynamic analysis of geographic atrophy ..., accessed August 15, 2025, https://pubmed.ncbi.nlm.nih.gov/39497616/
37. Pegcetacoplan Approved for Paroxysmal Nocturnal Hemoglobinuria | ASH Clinical News, accessed August 15, 2025, https://ashpublications.org/ashclinicalnews/news/5695/Pegcetacoplan-Approved-for-Paroxysmal-Nocturnal
38. Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ClinicalTrials.gov, accessed August 15, 2025, https://clinicaltrials.gov/study/NCT03500549
39. Pegcetacoplan (EMPAVELI) National Drug Monograph April 2023 - VA.gov, accessed August 15, 2025, https://www.va.gov/formularyadvisor/DOC_PDF/MON_Pegcetacoplan_EMPAVELI_Monograph_April_2023a.pdf
40. Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) - SFJ Pharmaceuticals, accessed August 15, 2025, https://sfj-pharma.com/apellis-reports-positive-top-line-results-from-phase-3-head-to-head-study-of-pegcetacoplan-apl-2-2/
41. Three Years On: The Role of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) since Its Initial Approval - PubMed Central, accessed August 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11354333/
42. A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH | ClinicalTrials.gov, accessed August 15, 2025, https://clinicaltrials.gov/study/NCT04085601
43. What clinical trials have been conducted for Pegcetacoplan? - Patsnap Synapse, accessed August 15, 2025, https://synapse.patsnap.com/article/what-clinical-trials-have-been-conducted-for-pegcetacoplan
44. EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH ..., accessed August 15, 2025, https://investors.apellis.com/news-releases/news-release-details/empavelir-pegcetacoplan-provided-long-term-control-pnh-new-data
45. Pegcetacoplan Long Term Safety and Efficacy Extension Study - ClinicalTrials.gov, accessed August 15, 2025, https://clinicaltrials.gov/study/NCT03531255
46. Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study - PubMed, accessed August 15, 2025, https://pubmed.ncbi.nlm.nih.gov/38573482/
47. Drug Approval for the Treatment of Geographic Atrophy: How We Got Here and Where We Need to Go - PMC, accessed August 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11162935/
48. Apellis Receives FDA Approval for SYFOVRE™ (pegcetacoplan injection) as the First Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness - Penn Center for Innovation, accessed August 15, 2025, https://pci.upenn.edu/apellis-receives-fda-approval-for-syfovre-pegcetacoplan-injection-as-the-first-and-only-treatment-for-geographic-atrophy-ga-a-leading-cause-of-blindness/
49. Ashkan M. Abbey, MD: 3-Year Efficacy of Pegcetacoplan for ..., accessed August 15, 2025, https://www.hcplive.com/view/ashkan-abbey-md-3-year-efficacy-pegcetacoplan-geographic-atrophy
50. SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA) - Apellis Pharmaceuticals, Inc., accessed August 15, 2025, https://investors.apellis.com/news-releases/news-release-details/syfovrer-pegcetacoplan-injection-preserved-visual-function-36
51. SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA), accessed August 15, 2025, https://investors.apellis.com/news-releases/news-release-details/syfovrer-pegcetacoplan-injection-continued-demonstrate
52. New Geographic Atrophy Drugs: The Good, the Bad, and the ..., accessed August 15, 2025, https://www.aao.org/eyenet/article/new-geographic-atrophy-drugs
53. An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE) - ClinicalTrials.gov, accessed August 15, 2025, https://clinicaltrials.gov/study/NCT04770545
54. Pegcetacoplan an Effective Treatment for Subfoveal GA - Retinal Physician, accessed August 15, 2025, https://www.retinalphysician.com/issues/2024/october/pegcetacoplan-treatment-for-subfoveal-ga/
55. Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis | ClinicalTrials.gov, accessed August 15, 2025, https://clinicaltrials.gov/study/NCT05067127?term=Pegcetacoplan%20AND%20C3&viewType=Table&rank=3
56. Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALIANT) - ClinicalTrials.gov, accessed August 15, 2025, https://clinicaltrials.gov/study/NCT05067127
57. Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN, accessed August 15, 2025, https://investors.apellis.com/news-releases/news-release-details/apellis-and-sobi-announce-positive-topline-results-phase-3
58. Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN | Sobi, accessed August 15, 2025, https://www.sobi.com/en/press-releases/pivotal-valiant-results-presented-kidney-week-show-pegcetacoplan-treatment-effect-patients-c3g-primary-ic-mpgn-2274618
59. ASN - American Society of Nephrology | Kidney Week - Abstract Details (2024), accessed August 15, 2025, https://www.asn-online.org/education/kidneyweek/2024/program-abstract.aspx?controlId=4176360
60. Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN, accessed August 15, 2025, https://investors.apellis.com/news-releases/news-release-details/apellis-and-sobi-announce-empavelir-pegcetacoplan-showed
61. Empaveli (pegcetacoplan) FDA Approval History - Drugs.com, accessed August 15, 2025, https://www.drugs.com/history/empaveli.html
62. Pegcetacoplan Side Effects: Common, Severe, Long Term, accessed August 15, 2025, https://www.drugs.com/sfx/pegcetacoplan-side-effects.html
63. SYFOVRE® (pegcetacoplan injection), accessed August 15, 2025, https://syfovreecp.com/
64. Pegcetacoplan | Aplastic Anemia and MDS International Foundation (AAMDSIF), accessed August 15, 2025, https://www.aamds.org/treatments/drugs/pegcetacoplan
65. Search Orphan Drug Designations and Approvals - accessdata.fda ..., accessed August 15, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=427614
66. FDA Approval of SYFOVRE (Pegcetacoplan) and IZERVAY (Avacincaptad Pegol) Reshapes Management of GA - American Health & Drug Benefits, accessed August 15, 2025, https://www.ahdbonline.com/issues/2023/september-2023-vol-16-payers-guide/fda-approval-of-syfovre-pegcetacoplan-and-izervay-avacincaptad-pegol-reshapes-management-of-ga
67. Pegcetacoplan: The FDA Approval Process - WebMD, accessed August 15, 2025, https://www.webmd.com/a-to-z-guides/pegcetacoplan-approval-process
68. Approval of pegcetacoplan for PNH patients, accessed August 15, 2025, https://aa-pnh.org/en/admission-of-pegcetacoplan-for-pnh-patients/
69. Syfovre FAQs and next steps for dry AMD and geographic atrophy treatment, accessed August 15, 2025, https://www.macularsociety.org/about/media/news/2025/february/syfovre-faqs-and-next-steps-for-dry-amd-and-geographic-atrophy-treatment/
70. Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH | Blood Advances | American Society of Hematology, accessed August 15, 2025, https://ashpublications.org/bloodadvances/article/8/7/1776/514813/Management-of-acute-breakthrough-hemolysis-with
71. SYFOVRE® (pegcetacoplan injection), for intravitreal use - accessdata.fda.gov, accessed August 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217171s002lbl.pdf
72. SYFOVRE® (pegcetacoplan injection) dosing, accessed August 15, 2025, https://syfovreecp.com/syfovre-dosing/
73. Clinical Trials - Therapeutics for Ophthalmology, Hematology, Nephrology & Gene Therapy | Apellis Pharmaceuticals, accessed August 15, 2025, https://apellis.com/our-science/clinical-trials/